{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:56:12Z","timestamp":1792461372437,"version":"4.5.0"},"reference-count":50,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2015,10,6]],"date-time":"2015-10-06T00:00:00Z","timestamp":1444089600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2015,10,6]],"date-time":"2015-10-06T00:00:00Z","timestamp":1444089600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions"}],"funder":[{"name":"Inserm, University of Strasbourg, the European Union","award":["EU-INTERREG-IV-Rhin Sup\u00e9rieur-FEDER Hepato-Regio-Net 2012"],"award-info":[{"award-number":["EU-INTERREG-IV-Rhin Sup\u00e9rieur-FEDER Hepato-Regio-Net 2012"]}]},{"name":"Inserm, University of Strasbourg, the European Union","award":["ERC-2008-AdG-33130-HEPCENT"],"award-info":[{"award-number":["ERC-2008-AdG-33130-HEPCENT"]}]},{"name":"Inserm, University of Strasbourg, the European Union","award":["FP7 305600 HepaMab"],"award-info":[{"award-number":["FP7 305600 HepaMab"]}]},{"name":"Inserm, University of Strasbourg, the European Union","award":["EU Infect-Era hepBccc"],"award-info":[{"award-number":["EU Infect-Era hepBccc"]}]},{"DOI":"10.13039\/501100003323","name":"ANRS","doi-asserted-by":"crossref","award":["2012\/318"],"award-info":[{"award-number":["2012\/318"]}],"id":[{"id":"10.13039\/501100003323","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003323","name":"ANRS","doi-asserted-by":"crossref","award":["2013\/108"],"award-info":[{"award-number":["2013\/108"]}],"id":[{"id":"10.13039\/501100003323","id-type":"DOI","asserted-by":"crossref"}]},{"name":"French Cancer Agency","award":["ARC IHU201301187"],"award-info":[{"award-number":["ARC IHU201301187"]}]},{"name":"French National Research Agency as part of the Investments for the future program"},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"crossref","award":["201411MFE-338606-245517"],"award-info":[{"award-number":["201411MFE-338606-245517"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Hepatology"],"published-print":{"date-parts":[[2016,1]]},"abstract":"<jats:p>\n                    Chronic hepatitis B and D infections are major causes of liver disease and hepatocellular carcinoma worldwide. Efficient therapeutic approaches for cure are absent. Sharing the same envelope proteins, hepatitis B virus and hepatitis delta virus use the sodium\/taurocholate cotransporting polypeptide (a bile acid transporter) as a receptor to enter hepatocytes. However, the detailed mechanisms of the viral entry process are still poorly understood. Here, we established a high\u2010throughput infectious cell culture model enabling functional genomics of hepatitis delta virus entry and infection. Using a targeted RNA interference entry screen, we identified glypican 5 as a common host cell entry factor for hepatitis B and delta viruses.\n                    <jats:italic toggle=\"yes\">Conclusion<\/jats:italic>\n                    : These findings advance our understanding of virus cell entry and open new avenues for curative therapies. As glypicans have been shown to play a role in the control of cell division and growth regulation, virus\u2013glypican 5 interactions may also play a role in the pathogenesis of virus\u2010induced liver disease and cancer. (H\n                    <jats:sc>epatology<\/jats:sc>\n                    2016;63:35\u201348)\n                  <\/jats:p>","DOI":"10.1002\/hep.28013","type":"journal-article","created":{"date-parts":[[2015,7,29]],"date-time":"2015-07-29T21:03:21Z","timestamp":1438203801000},"page":"35-48","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":193,"title":["A targeted functional RNA interference screen uncovers glypican 5 as an entry factor for hepatitis B and D viruses"],"prefix":"10.1097","volume":"63","author":[{"given":"Eloi R.","family":"Verrier","sequence":"first","affiliation":[{"name":"Inserm, U1110, Institut de Recherche sur les Maladies Virales et H\u00e9patiques,Strasbourg,France"},{"name":"Universit\u00e9 de Strasbourg,Strasbourg,France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Che C.","family":"Colpitts","sequence":"additional","affiliation":[{"name":"Inserm, U1110, Institut de Recherche sur les Maladies Virales et H\u00e9patiques,Strasbourg,France"},{"name":"Universit\u00e9 de Strasbourg,Strasbourg,France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Bach","sequence":"additional","affiliation":[{"name":"Inserm, U1110, Institut de Recherche sur les Maladies Virales et H\u00e9patiques,Strasbourg,France"},{"name":"Universit\u00e9 de Strasbourg,Strasbourg,France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Heydmann","sequence":"additional","affiliation":[{"name":"Inserm, U1110, Institut de Recherche sur les Maladies Virales et H\u00e9patiques,Strasbourg,France"},{"name":"Universit\u00e9 de Strasbourg,Strasbourg,France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Am\u00e9lie","family":"Weiss","sequence":"additional","affiliation":[{"name":"IGBMC, Plateforme de Criblage Haut\u2010d\u00e9bit,Illkirch,France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micka\u00ebl","family":"Renaud","sequence":"additional","affiliation":[{"name":"IGBMC, Plateforme de Criblage Haut\u2010d\u00e9bit,Illkirch,France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah C.","family":"Durand","sequence":"additional","affiliation":[{"name":"Inserm, U1110, Institut de Recherche sur les Maladies Virales et H\u00e9patiques,Strasbourg,France"},{"name":"Universit\u00e9 de Strasbourg,Strasbourg,France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Habersetzer","sequence":"additional","affiliation":[{"name":"Institut Hospitalo\u2010Universitaire, P\u00f4le H\u00e9pato\u2010digestif, Nouvel H\u00f4pital Civil,Strasbourg,France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Durantel","sequence":"additional","affiliation":[{"name":"Inserm, U1052, CNRS UMR 5286, Cancer Research Center of Lyon, Universit\u00e9 de Lyon,Lyon,France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georges","family":"Abou\u2010Jaoud\u00e9","sequence":"additional","affiliation":[{"name":"INTS, Laboratoire de Virologie Mol\u00e9culaire,Paris,France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria M.","family":"L\u00f3pez Ledesma","sequence":"additional","affiliation":[{"name":"C\u00e1tedra de Virolog\u00eda, Facultad de Farmacia y Bioqu\u00edmica, Universidad de Buenos Aires,Buenos Aires,Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Felmlee","sequence":"additional","affiliation":[{"name":"Inserm, U1110, Institut de Recherche sur les Maladies Virales et H\u00e9patiques,Strasbourg,France"},{"name":"Universit\u00e9 de Strasbourg,Strasbourg,France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magali","family":"Soumillon","sequence":"additional","affiliation":[{"name":"Broad Institute of Massachusetts Institute of Technology and Harvard,Cambridge,MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Croonenborghs","sequence":"additional","affiliation":[{"name":"Program in Translational NeuroPsychiatric Genomics, Brigham and Women's Hospital, Harvard Medical School, Broad Institute of Massachusetts Institute of Technology and Harvard,Cambridge,MA"},{"name":"KU Leuven Technology Campus Geel,AdvISe,Geel,Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Pochet","sequence":"additional","affiliation":[{"name":"Program in Translational NeuroPsychiatric Genomics, Brigham and Women's Hospital, Harvard Medical School, Broad Institute of Massachusetts Institute of Technology and Harvard,Cambridge,MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Nassal","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II\/Molecular Biology,University Hospital Freiburg,Freiburg,Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Schuster","sequence":"additional","affiliation":[{"name":"Inserm, U1110, Institut de Recherche sur les Maladies Virales et H\u00e9patiques,Strasbourg,France"},{"name":"Universit\u00e9 de Strasbourg,Strasbourg,France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Brino","sequence":"additional","affiliation":[{"name":"IGBMC, Plateforme de Criblage Haut\u2010d\u00e9bit,Illkirch,France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Sureau","sequence":"additional","affiliation":[{"name":"INTS, Laboratoire de Virologie Mol\u00e9culaire,Paris,France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjam B.","family":"Zeisel","sequence":"additional","affiliation":[{"name":"Inserm, U1110, Institut de Recherche sur les Maladies Virales et H\u00e9patiques,Strasbourg,France"},{"name":"Universit\u00e9 de Strasbourg,Strasbourg,France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas F.","family":"Baumert","sequence":"additional","affiliation":[{"name":"Inserm, U1110, Institut de Recherche sur les Maladies Virales et H\u00e9patiques,Strasbourg,France"},{"name":"Universit\u00e9 de Strasbourg,Strasbourg,France"},{"name":"Institut Hospitalo\u2010Universitaire, P\u00f4le H\u00e9pato\u2010digestif, Nouvel H\u00f4pital Civil,Strasbourg,France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2015,10,6]]},"reference":[{"key":"hep28013-bib-0001-20241017","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1055\/s-0033-1345717","article-title":"The molecular virology of hepatitis B virus","volume":"33","year":"2013","journal-title":"Semin Liver Dis"},{"key":"hep28013-bib-0002-20241017","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/S0140-6736(14)60220-8","article-title":"Hepatitis B virus infection","volume":"384","year":"2014","journal-title":"Lancet"},{"key":"hep28013-bib-0003-20241017","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1136\/gut.46.3.420","article-title":"Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep)","volume":"46","year":"2000","journal-title":"Gut"},{"key":"hep28013-bib-0004-20241017","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-0032-1323623","article-title":"Virology of hepatitis D virus","volume":"32","year":"2012","journal-title":"Semin Liver Dis"},{"key":"hep28013-bib-0005-20241017","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S1473-3099(11)70314-0","article-title":"Selection of chronic hepatitis B therapy with high barrier to resistance","volume":"12","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"hep28013-bib-0006-20241017","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa0912696","article-title":"Peginterferon plus adefovir versus either drug alone for hepatitis delta","volume":"364","year":"2011","journal-title":"N Engl J Med"},{"key":"hep28013-bib-0007-20241017","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nrgastro.2013.164","article-title":"Chronic hepatitis D at a standstill: where do we go from here?","volume":"11","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"hep28013-bib-0008-20241017","doi-asserted-by":"crossref","first-page":"e00049","DOI":"10.7554\/eLife.00049","article-title":"Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus","volume":"1","year":"2012","journal-title":"Elife"},{"key":"hep28013-bib-0009-20241017","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1053\/j.gastro.2013.12.024","article-title":"Hepatitis B and D viruses exploit sodium taurocholate co\u2010transporting polypeptide for species\u2010specific entry into hepatocytes","volume":"146","year":"2014","journal-title":"Gastroenterology"},{"key":"hep28013-bib-0010-20241017","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.3390\/ijms15022892","article-title":"NTCP and beyond: opening the door to unveil hepatitis B virus entry","volume":"15","year":"2014","journal-title":"Int J Mol Sci"},{"key":"hep28013-bib-0011-20241017","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1038\/nature05817","article-title":"Heparan sulphate proteoglycans fine\u2010tune mammalian physiology","volume":"446","year":"2007","journal-title":"Nature"},{"key":"hep28013-bib-0012-20241017","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S1016-8478(23)14017-9","article-title":"Microbial subversion of heparan sulfate proteoglycans","volume":"26","year":"2008","journal-title":"Mol Cells"},{"key":"hep28013-bib-0013-20241017","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1002\/hep.21896","article-title":"Hepatitis B virus infection initiates with a large surface protein\u2010dependent binding to heparan sulfate proteoglycans","volume":"46","year":"2007","journal-title":"Hepatology"},{"key":"hep28013-bib-0014-20241017","doi-asserted-by":"crossref","first-page":"e58340","DOI":"10.1371\/journal.pone.0058340","article-title":"Proteoglycans act as cellular hepatitis delta virus attachment receptors","volume":"8","year":"2013","journal-title":"PLoS One"},{"key":"hep28013-bib-0015-20241017","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1002\/hep.26125","article-title":"A conformational heparan sulfate binding site essential to infectivity overlaps with the conserved hepatitis B virus a\u2010determinant","volume":"57","year":"2013","journal-title":"Hepatology"},{"key":"hep28013-bib-0016-20241017","first-page":"58","article-title":"Entry of hepatitis B and C viruses\u2014recent progress and future impact","volume":"4C","year":"2014","journal-title":"Curr Opin Virol"},{"key":"hep28013-bib-0017-20241017","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1053\/j.gastro.2014.04.030","article-title":"Strategies to inhibit entry of HBV and HDV into hepatocytes","volume":"147","year":"2014","journal-title":"Gastroenterology"},{"key":"hep28013-bib-0018-20241017","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1002\/hep.26982","article-title":"Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP)","volume":"59","year":"2014","journal-title":"Hepatology"},{"key":"hep28013-bib-0019-20241017","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.jhep.2012.12.008","article-title":"The entry inhibitor Myrcludex\u2010B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus","volume":"58","year":"2013","journal-title":"J Hepatol"},{"key":"hep28013-bib-0020-20241017","first-page":"1279a","article-title":"A proof\u2010of\u2010concept phase 2a clinical trial with HBV\/HDV entry inhibitor Myrcludex B","volume":"60","year":"2014","journal-title":"Hepatology"},{"key":"hep28013-bib-0021-20241017","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.antiviral.2014.03.017","article-title":"Use of FDA approved therapeutics with hNTCP metabolic inhibitory properties to impair the HDV lifecycle","volume":"106","year":"2014","journal-title":"Antiviral Res"},{"key":"hep28013-bib-0022-20241017","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/nm.2341","article-title":"EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy","volume":"17","year":"2011","journal-title":"Nat Med"},{"key":"hep28013-bib-0023-20241017","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1128\/AAC.41.8.1715","article-title":"Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication","volume":"41","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"hep28013-bib-0024-20241017","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/978-1-60761-688-7_25","article-title":"The use of hepatocytes to investigate HDV infection: the HDV\/HepaRG model","volume":"640","year":"2010","journal-title":"Methods Mol Biol"},{"key":"hep28013-bib-0025-20241017","doi-asserted-by":"crossref","first-page":"5841","DOI":"10.1128\/JVI.00096-07","article-title":"Infectivity determinants of the hepatitis B virus pre\u2010S domain are confined to the N\u2010terminal 75 amino acid residues","volume":"81","year":"2007","journal-title":"J Virol"},{"key":"hep28013-bib-0026-20241017","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/liv.12661","article-title":"Loss of hepatitis B surface antigen in a real\u2010life clinical cohort of patients with chronic hepatitis B virus infection","volume":"35","year":"2015","journal-title":"Liver Int"},{"key":"hep28013-bib-0027-20241017","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/hep.21299","article-title":"Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients","volume":"44","year":"2006","journal-title":"Hepatology"},{"key":"hep28013-bib-0028-20241017","doi-asserted-by":"crossref","first-page":"9786","DOI":"10.1128\/JVI.79.15.9786-9798.2005","article-title":"Mapping of the hepatitis B virus pre\u2010S1 domain involved in receptor recognition","volume":"79","year":"2005","journal-title":"J Virol"},{"key":"hep28013-bib-0029-20241017","doi-asserted-by":"crossref","first-page":"15655","DOI":"10.1073\/pnas.232137699","article-title":"Infection of a human hepatoma cell line by hepatitis B virus","volume":"99","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"hep28013-bib-0030-20241017","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/hep.20553","article-title":"Hepatitis B virus mutations associated with fulminant hepatitis induce apoptosis in primary Tupaia hepatocytes","volume":"41","year":"2005","journal-title":"Hepatology"},{"key":"hep28013-bib-0031-20241017","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1128\/JVI.75.3.1104-1116.2001","article-title":"Hepatitis B virus (HBV) virion and covalently closed circular DNA formation in primary tupaia hepatocytes and human hepatoma cell lines upon HBV genome transduction with replication\u2010defective adenovirus vectors","volume":"75","year":"2001","journal-title":"J Virol"},{"key":"hep28013-bib-0032-20241017","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.bbrc.2013.12.052","article-title":"Evaluation and identification of hepatitis B virus entry inhibitors using HepG2 cells overexpressing a membrane transporter NTCP","volume":"443","year":"2014","journal-title":"Biochem Biophys Res Commun"},{"key":"hep28013-bib-0033-20241017","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.jhep.2013.11.022","article-title":"Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin\u2010independent interference with the NTCP receptor","volume":"60","year":"2014","journal-title":"J Hepatol"},{"key":"hep28013-bib-0034-20241017","doi-asserted-by":"crossref","first-page":"e95550","DOI":"10.1371\/journal.pone.0095550","article-title":"Syndecan 4 is involved in mediating HCV entry through interaction with lipoviral particle\u2010associated apolipoprotein E","volume":"9","year":"2014","journal-title":"PLoS One"},{"key":"hep28013-bib-0035-20241017","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1006\/viro.1993.1069","article-title":"Reproducible high level infection of cultured adult human hepatocytes by hepatitis B virus: effect of polyethylene glycol on adsorption and penetration","volume":"192","year":"1993","journal-title":"Virology"},{"key":"hep28013-bib-0036-20241017","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s00204-011-0782-2","article-title":"Diverse effects of dimethyl sulfoxide (DMSO) on the differentiation potential of human embryonic stem cells","volume":"86","year":"2012","journal-title":"Arch Toxicol"},{"key":"hep28013-bib-0037-20241017","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/gb-2008-9-5-224","article-title":"Glypicans","volume":"9","year":"2008","journal-title":"Genome Biol"},{"key":"hep28013-bib-0038-20241017","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0304-4165(02)00390-2","article-title":"The role of glypicans in mammalian development","volume":"1573","year":"2002","journal-title":"Biochim Biophys Acta"},{"key":"hep28013-bib-0039-20241017","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/ng.792","article-title":"Common variation in GPC5 is associated with acquired nephrotic syndrome","volume":"43","year":"2011","journal-title":"Nat Genet"},{"key":"hep28013-bib-0040-20241017","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/(SICI)1098-2264(200006)28:2<220::AID-GCC11>3.0.CO;2-T","article-title":"A novel and consistent amplicon at 13q31 associated with alveolar rhabdomyosarcoma","volume":"28","year":"2000","journal-title":"Genes Chromosomes Cancer"},{"key":"hep28013-bib-0041-20241017","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S1470-2045(10)70042-5","article-title":"Genetic variants and risk of lung cancer in never smokers: a genome\u2010wide association study","volume":"11","year":"2010","journal-title":"Lancet Oncol"},{"key":"hep28013-bib-0042-20241017","doi-asserted-by":"crossref","first-page":"32193","DOI":"10.1074\/jbc.M503645200","article-title":"Chondroitin sulfate characterized by the E\u2010disaccharide unit is a potent inhibitor of herpes simplex virus infectivity and provides the virus binding sites on gro2C cells","volume":"280","year":"2005","journal-title":"J Biol Chem"},{"key":"hep28013-bib-0043-20241017","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1128\/JVI.80.7.3487-3494.2006","article-title":"Porcine circovirus 2 uses heparan sulfate and chondroitin sulfate B glycosaminoglycans as receptors for its attachment to host cells","volume":"80","year":"2006","journal-title":"J Virol"},{"key":"hep28013-bib-0044-20241017","doi-asserted-by":"crossref","first-page":"6866","DOI":"10.1128\/JVI.03475-12","article-title":"Syndecan\u20101 serves as the major receptor for attachment of hepatitis C virus to the surfaces of hepatocytes","volume":"87","year":"2013","journal-title":"J Virol"},{"key":"hep28013-bib-0045-20241017","doi-asserted-by":"crossref","first-page":"41003","DOI":"10.1074\/jbc.M302267200","article-title":"Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate","volume":"278","year":"2003","journal-title":"J Biol Chem"},{"key":"hep28013-bib-0046-20241017","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1002\/hep.27159","article-title":"Binding of hepatitis B virus to its cellular receptor alters the expression profile of genes of bile acid metabolism","volume":"60","year":"2014","journal-title":"Hepatology"},{"key":"hep28013-bib-0047-20241017","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nbt.3179","article-title":"Clearance of persistent hepatitis C virus infection using a monoclonal antibody specific for thight junction protein claudin\u20101","volume":"33","year":"2015","journal-title":"Nat Biotechnol"},{"key":"hep28013-bib-0048-20241017","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ejca.2010.10.024","article-title":"Glypican\u20103: a new target for cancer immunotherapy","volume":"47","year":"2011","journal-title":"Eur J Cancer"},{"key":"hep28013-bib-0049-20241017","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1083\/jcb.201008087","article-title":"Glypican\u20105 stimulates rhabdomyosarcoma cell proliferation by activating Hedgehog signaling","volume":"192","year":"2011","journal-title":"J Cell Biol"},{"key":"hep28013-bib-0050-20241017","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1158\/0008-5472.CAN-06-1650","article-title":"Role for amplification and expression of glypican\u20105 in rhabdomyosarcoma","volume":"67","year":"2007","journal-title":"Cancer Res"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.28013","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.28013","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201601000-00012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T20:11:48Z","timestamp":1729195908000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201601000-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,6]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.28013","relation":{},"ISSN":["0270-9139","1527-3350"],"issn-type":[{"value":"0270-9139","type":"print"},{"value":"1527-3350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,6]]},"assertion":[{"value":"2015-03-25","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-07-23","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}